尤瑞克林治疗40例急性脑梗死的疗效观察  

Clinical Observation on the Efficacy of Kallikrein in the Treatment of 40 Patients with Acute Cerebral Infarction

作　　者：张以善[1] 张雄伟[1] 林浩[1] 王超凡[1] 王磊[1] 

机构地区：[1]解放军第二炮兵总医院神经内科,北京100088

出　　处：《医学临床研究》2009年第3期414-416,共3页Journal of Clinical Research

摘　　要：[目的]观察尤瑞克林治疗急性脑梗死的有效性和安全性。[方法]80例急性脑梗死患者随机分成尤瑞克林治疗组（40例）及对照组（40例）。对照组用常规治疗方法，治疗组在常规治疗的基础上加用尤瑞克林治疗14d。采用NIHSS评分量表对治疗前、治疗后d7、d14的神经功能缺损进行评分和临床疗效评定，并记录不良反应。【结果】两组治疗后d7和d14NHISS评分均有改善（全部P〈0．05），治疗组优于对照组（全部P〈0．05）；治疗组总有效率达到90％显著高于对照组的70％（P〈0．05）。两组均未发现明显不良反应。[结论]尤瑞克林能显著改善急性脑梗死的神经功能缺损，提高疗效，安全性高。[Objective]To evaluate the efficacy and safe of Kallikrein on acute cerebral infarction （ACI） . [Methods]Eighty patients with ACI were randomly allocated into treatment group （ n =40） and control group （ n =40）. Patients in both groups were given general supportive care. Patients in treatment group also received kallikrein injection 0. 15PNA once per day for 14 days. The neurological deficits were assessed by Stroke Scale （NIHSS） before and after the treatment, respectively. Clinical efficacy was evaluated according to changes of NIHSS. [Results] The 7d and 14d NIHSS score of two groups were improved （all P 〈0.05）. There was a significant difference in NIHSS score between treatment group and control group （ P 〈0.05）. There was no distinct adverse reaction in two groups. [Conclusion] Kallikrein can improve significantly and safely the neurological deficits. It is worthy to be recommended for clinical application.

关 键 词：脑梗塞/药物疗法 急性病 

分 类 号：R743.33[医药卫生—神经病学与精神病学]